Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Policy / Regulatory

WuXi Biologics’ Shanghai Subsidiary Removed from US UVL

Fineline Cube Dec 16, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Policy / Regulatory

Liaoning Publishes Fourth Round of Volume-Based Procurement Winning Bids

Fineline Cube Dec 16, 2022

The Liaoning drug and medical consumables centralized procurement website has published the fourth round of...

Company Deals

Cryofocus Medtech Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 16, 2022

China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set...

Company Medical Device

NMPA Approves SonoScape and Acoustic Life’s Intravascular Ultrasound Products

Fineline Cube Dec 16, 2022

The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound...

Company Drug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

Fineline Cube Dec 15, 2022

German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...

Drug

Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China

Fineline Cube Dec 15, 2022

Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...

Company Medical Device

Acotec Scientific’s NEO-Skater Balloon Approved by NMPA for Intracranial Vessels

Fineline Cube Dec 15, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National...

Company Drug

Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial

Fineline Cube Dec 15, 2022

China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...

Company Drug

Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC

Fineline Cube Dec 15, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...

Company Drug

Henlius Biotech Initiates Phase I Trial for HLX60 in Australia

Fineline Cube Dec 15, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...

Company Deals

China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China

Fineline Cube Dec 15, 2022

China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...

Company Medical Device

Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter

Fineline Cube Dec 15, 2022

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Company Deals

Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics

Fineline Cube Dec 15, 2022

Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program

Fineline Cube Dec 14, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...

Company Digital Drug

111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China

Fineline Cube Dec 14, 2022

China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...

Company Deals

Biosion and ImmunoGen Collaborate on Cancer ADCs

Fineline Cube Dec 14, 2022

China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...

Company Deals

Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics

Fineline Cube Dec 14, 2022

UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...

Company Deals

Henlius Biotech Partners with Medilink for Global ADC Development

Fineline Cube Dec 14, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...

Posts pagination

1 … 639 640 641 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.